CD1d–lipid antigen complex (CD1d-Ag)

The CD1d–lipid antigen complex is a molecular assembly comprising the CD1d glycoprotein and a lipidic or glycolipidic ligand (UniProt: P15813). CD1d is a member of the CD1 family of MHC class I-like molecules that specialize in presenting lipid antigens rather than peptide fragments to T cells (PubMed: 11244037). This complex is primarily recognized by the semi-invariant T-cell receptor (TCR) of invariant Natural Killer T (iNKT) cells, serving as a critical bridge between the innate and adaptive immune systems (PubMed: 24510453). Therapeutic targeting of this complex involves the use of synthetic glycolipids, such as alpha-galactosylceramide, to modulate NKT cell activity for treating cancer, chronic infections, and autoimmune disorders (PubMed: 29461468). The specific chemical structure of the lipid antigen within the CD1d binding groove determines the duration of the interaction and the resulting cytokine signaling profile, which is essential for achieving therapeutic efficacy while avoiding NKT cell exhaustion or anergy (PubMed: 17237759).

Other names

CD1d-glycolipid complexCD1d-alpha-GalCer complexCD1.1R3G1CD1d1

The complex acts as a ligand for the T-cell receptor (TCR) of Natural Killer T (NKT) cells, leading to their rapid activation and the subsequent release of Th1 and Th2 cytokines.